This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with interest the recent article by Rappelle et al.1 They report data of a retrospective study on chemotherapy with vincristine (PCV) in 63 patients with recurrent glioblastoma.
In line with literature data,2 their median time to tumor progression (TTP) and survival time (ST) values were related to young age and postsurgery Karnofsky performance status (KPS); also, they were not different in 26 patients undergoing a second resection.
We report the clinical data pertaining to 47 patients with recurrent glioblastoma followed prospectively in our institution and treated homogeneously before relapse (i.e., surgery, followed by radiotherapy and systemic chemotherapy with carmustine and cisplatin every 6 weeks).
Patients were included in the study if they were between the ages of 18 and 65 and had histological diagnosis …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
